Free Trial

Annexon (ANNX) Competitors

Annexon logo
$2.55 +0.07 (+2.82%)
Closing price 07/24/2025 04:00 PM Eastern
Extended Trading
$2.58 +0.03 (+1.14%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANNX vs. GHRS, AKBA, SANA, ZYME, COLL, SYRE, RCUS, VERV, AMPH, and AVXL

Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include GH Research (GHRS), Akebia Therapeutics (AKBA), Sana Biotechnology (SANA), Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Verve Therapeutics (VERV), Amphastar Pharmaceuticals (AMPH), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry.

Annexon vs. Its Competitors

Annexon (NASDAQ:ANNX) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

GH Research is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnnexonN/AN/A-$138.20M-$1.18-2.16
GH ResearchN/AN/A-$38.96M-$0.79-18.34

In the previous week, GH Research had 4 more articles in the media than Annexon. MarketBeat recorded 6 mentions for GH Research and 2 mentions for Annexon. GH Research's average media sentiment score of 0.57 beat Annexon's score of 0.29 indicating that GH Research is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Annexon
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
GH Research
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

56.9% of GH Research shares are owned by institutional investors. 11.9% of Annexon shares are owned by insiders. Comparatively, 41.6% of GH Research shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GH Research's return on equity of -19.20% beat Annexon's return on equity.

Company Net Margins Return on Equity Return on Assets
AnnexonN/A -54.45% -46.56%
GH Research N/A -19.20%-18.40%

Annexon currently has a consensus target price of $12.50, indicating a potential upside of 390.20%. GH Research has a consensus target price of $32.00, indicating a potential upside of 120.84%. Given Annexon's higher possible upside, equities research analysts clearly believe Annexon is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annexon
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
GH Research
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Annexon has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

GH Research beats Annexon on 9 of the 12 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANNX vs. The Competition

MetricAnnexonMED IndustryMedical SectorNASDAQ Exchange
Market Cap$272.09M$3.05B$5.72B$9.47B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.1620.8627.9419.95
Price / SalesN/A317.05452.94100.82
Price / CashN/A43.2336.5558.97
Price / Book0.938.308.645.90
Net Income-$138.20M-$55.19M$3.24B$258.42M
7 Day Performance9.91%5.81%3.69%2.11%
1 Month Performance6.69%17.73%10.33%12.44%
1 Year Performance-58.70%4.67%34.30%19.55%

Annexon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANNX
Annexon
2.3702 of 5 stars
$2.55
+2.8%
$12.50
+390.2%
-58.1%$272.09MN/A-2.1660Gap Up
GHRS
GH Research
2.0984 of 5 stars
$19.50
+11.0%
$32.00
+64.1%
+22.8%$1.01BN/A-24.6810
AKBA
Akebia Therapeutics
3.8477 of 5 stars
$3.84
-0.5%
$6.75
+75.8%
+161.2%$1.01B$160.18M0.00430Positive News
SANA
Sana Biotechnology
3.2338 of 5 stars
$4.44
-4.1%
$9.17
+106.5%
-16.2%$1.00BN/A-5.05380Gap Up
ZYME
Zymeworks
2.9581 of 5 stars
$14.32
+0.5%
$21.00
+46.6%
+34.7%$997.86M$93.38M-9.55460Upcoming Earnings
COLL
Collegium Pharmaceutical
4.4785 of 5 stars
$30.91
-0.9%
$43.75
+41.5%
-6.5%$993.14M$631.45M25.34210Positive News
SYRE
Spyre Therapeutics
2.5426 of 5 stars
$16.35
+0.4%
$53.40
+226.6%
-42.7%$985.58M$890K-4.3473Positive News
RCUS
Arcus Biosciences
1.6818 of 5 stars
$9.27
+1.3%
$21.29
+129.7%
-32.2%$981.18M$258M-2.21500
VERV
Verve Therapeutics
2.9104 of 5 stars
$10.93
+0.2%
$14.57
+33.3%
+57.2%$974.30M$32.33M-5.18110News Coverage
AMPH
Amphastar Pharmaceuticals
4.4658 of 5 stars
$21.19
+2.8%
$32.33
+52.6%
-45.4%$972.01M$731.97M6.532,028
AVXL
Anavex Life Sciences
4.0078 of 5 stars
$11.16
+1.6%
$44.00
+294.3%
+97.2%$953.29MN/A-20.2940Positive News

Related Companies and Tools


This page (NASDAQ:ANNX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners